Pfizer’s Hympavzi secures FDA expanded indications for haemophilia

Pharmaceutical Technology

Pfizer has received approval from the FDA for an expanded indication of Hympavzi for the treatment of haemophilia A or B.

pharminent June 9, 2026 (Last updated: June 9, 2026)

Pharmaceutical Technology

Pfizer has received approval from the FDA for an expanded indication of Hympavzi for the treatment of haemophilia A or B.

Related Stories